Cited in:


This article has been cited by:

  1. 1
    Poonam Mishra, Jeffrey Murray, Debra Birnkrant, Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs, Hepatology, 2015, 62, 2
  2. 2
    T Pene Dumitrescu, MJ Fossler, VD Schmith, Pharmacometrics: Focus on the Patient, CPT: Pharmacometrics & Systems Pharmacology, 2015, 4, 1
  3. 3
    Marc G. Ghany, T. Jake Liang, Building Bridges and Providing Transparency to the Hepatitis C Virus Drug Approval Process, Gastroenterology, 2014, 147, 6, 1201


  4. 4
    Poonam Mishra, Jeffry Florian, Jeffrey Murray, FDA bridging analyses confirmed in clinical trial, Hepatology, 2014, 60, 6
  5. 5
    Poonam Mishra, Jeffry Florian, Karen Qi, Wen Zeng, Lisa K. Naeger, Eric Donaldson, Sarah Connelly, Jules O’Rear, Dionne Price, Jeffrey Murray, Debra Birnkrant, FDA Perspective on Sofosbuvir Therapy for Patients With Chronic Hepatitis C Virus Genotype 1 Infection Who Did Not Respond to Treatment With Pegylated Interferon and Ribavirin, Gastroenterology, 2014, 147, 6, 1196


  6. You have free access to this content6
    Benjamin Maasoumy, Michael P. Manns, Optimal treatment with boceprevir for chronic HCV infection, Liver International, 2013, 33,
  7. 7
    Michael W. Fried, Donald M. Jensen, The FDA, bridging data, and hepatitis C, Hepatology, 2013, 57, 3
  8. You have free access to this content8
    Shiew-Mei Huang, Darrell R. Abernethy, Yaning Wang, Ping Zhao, Issam Zineh, The utility of modeling and simulation in drug development and regulatory review, Journal of Pharmaceutical Sciences, 2013, 102, 9